Chongqing Primary Aldosteronism Study

ConditionPrimary Aldosteronism

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-80

SponsorChongqing Medical University

About this trial

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Eligibility criteria

Qualifiers

hypertensive patients who completed ARR screening and necessary further tests;

Voluntary to sign the informed consent.

Disqualifiers

patients with severe cardiac, hepatic or renal dysfunction;

suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Trial design

Treatments tested in this trial

no intervention

Treatment groups

1,500 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Chongqing Medical University

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Sponsor institution

Source ClinicalTrials.gov